Beijing Tiantan Biological Products Co., Ltd. (SHA:600161)

Market Cap	40.30B
Revenue (ttm)	5.23B
Net Income (ttm)	1.27B
Shares Out	1.98B
EPS (ttm)	0.64
PE Ratio	31.94
Forward PE	25.18
Dividend	0.13 (0.62%)
Ex-Dividend Date	Jun 20, 2024

Volume	15,001,436
Average Volume	10,546,251
Open	20.13
Previous Close	20.17
Day's Range	20.07 - 20.45
52-Week Range	18.88 - 27.60
Beta	0.44
RSI	50.15
Earnings Date	Mar 29, 2025

About SHA:600161

Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationlly. Its products include human albumin; intravenous human immunoglobulin; rabies patient immunoglobulin; tetanus human immunoglobulin; hepatitis B human immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamine human immunoglobulin; human prothrombin complex; human coagulation factors VIII; human fibrinogen; recombinant human coagulation factor VIII for inje...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1966
• Employees: 4,858
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600161

Financial Performance

In 2023, SHA:600161's revenue was 5.18 billion, an increase of 21.57% compared to the previous year's 4.26 billion. Earnings were 1.11 billion, an increase of 25.99%.